Red Light Therapy and Arterial Plaque

A Viral Thread, a Rabbit Study, and a Very Big Claim

A thread went viral this week claiming that an "incredible study" showed red light therapy could reduce arterial plaque more effectively than statins. The post racked up over 76,000 views in hours. The implication was breathtaking: forget your Lipitor — just shine a light on your body and watch the plaque melt away.

The biohacker and longevity communities have been circulating this idea for months, fueled by a handful of studies that — on first glance — seem almost too good to be true. Red light panels, already marketed for skin rejuvenation, pain relief, and testosterone optimization, now apparently reverse cardiovascular disease too. If you believe the marketing, a $500 light panel is the new statin.

I wanted this to be true. The mechanism is elegant, and anything that might reduce the global burden of cardiovascular disease — the number one killer worldwide — deserves serious attention. So I did what I always do: I pulled up the actual studies. And what I found was a textbook case of extraordinary preclinical data being extrapolated far beyond what the evidence supports.

Let me walk you through what's real, what's promising, and what's marketing fantasy.

Why Shining Light on Your Body Isn't as Crazy as It Sounds

Photobiomodulation (PBM) — the clinical term for red and near-infrared light therapy — works through a mechanism that is genuinely well-characterized. Red light in the 600–1100 nm wavelength range penetrates tissue and is absorbed by cytochrome c oxidase, a key enzyme in the mitochondrial electron transport chain (Complex IV).¹

When this enzyme absorbs photons, it triggers a cascade of downstream effects: increased ATP production, release of nitric oxide (NO) from the enzyme's binding sites, and a temporary boost in cellular energy metabolism.² The nitric oxide release is particularly relevant to cardiovascular health — NO is the body's primary vasodilator, and impaired NO signaling is a hallmark of endothelial dysfunction, the earliest stage of atherosclerosis.³

There's also emerging evidence that PBM can modulate macrophage behavior. A 2021 study demonstrated that red light therapy upregulates the ABCA1 transporter on macrophages — the molecular pump responsible for moving cholesterol out of cells and into HDL particles.⁴ In theory, this could reduce foam cell formation, a critical early step in plaque development. The researchers showed that PBM-treated mice on a Western diet had significantly higher HDL cholesterol levels.

So the biological plausibility is real. The question is whether any of this translates to actual plaque reduction in living human arteries. And that's where the story gets considerably less impressive.

54% Plaque Reduction — in Rabbits on a Cholesterol-Bomb Diet

The study at the center of the viral claim is Park et al. (2012), published in Laboratory Animal Research.⁵ It's the study that started this conversation, and it deserves a close reading — because both the results and the limitations are instructive.

Let me be clear about what this study actually showed: polarized light — not standard red light therapy as sold in consumer panels — reduced plaque in rabbits fed an extreme cholesterol diet. The 400–760 nm wavelength range used is broader than what most consumer panels emit (typically 630–660 nm red and 810–850 nm near-infrared). And the delivery method — polarized light from a clinical-grade 60W device applied directly — bears little resemblance to sitting in front of a Joovv panel in your bathroom.⁵

Most importantly: this study was published in 2012. If these results were as transformative as the viral thread suggests, you'd expect follow-up studies, replication attempts, and at minimum a pilot human trial by now. Thirteen years later, there are none specifically following up on this work.

Mice That Lived Longer, Macrophages That Behaved, and No Human Arteries

The Park rabbit study isn't entirely alone. There's a small constellation of preclinical studies that collectively paint an intriguing — if incomplete — picture.

There's also a body of work on PBM and endothelial function. A 2022 study in Frontiers in Physiology demonstrated that red light at 670 nm could stimulate nitric oxide release from vascular endothelium, independent of the standard NOS enzyme pathway.⁷ This is mechanistically interesting because endothelial dysfunction is the earliest detectable phase of atherosclerosis — but "improving endothelial function" and "reversing established plaque" are very different clinical endpoints.

A separate 2017 systematic review in Scientific Reports examined PBM for myocardial ischemia-reperfusion injury and found promising animal data but noted the near-total absence of human trials.⁸

Where Are the Human Trials? Looking Hard and Finding Almost Nothing

If you're hoping I've buried the human evidence until now for dramatic effect — I haven't. For non-invasive photobiomodulation and atherosclerosis specifically, there are no published randomized controlled trials in humans.

Let me tell you what does exist, because it's important to be precise about what "no evidence" means.

There's also a historical curiosity: in the late 1990s and early 2000s, several groups tested intravascular red light therapy (IRLT) — threading a laser catheter directly into coronary arteries after stenting. One trial of 68 patients achieved a 14.7% restenosis rate compared to the then-typical 20–30%.¹⁰ But this approach was rendered obsolete by drug-eluting stents, which are far more effective and don't require a laser catheter inside your artery. It's a fascinating footnote, not a foundation for consumer light panel claims.

The most relevant ongoing trial is the LIGHT PAD study (NCT06165016) — a Phase II, double-blind, sham-controlled RCT testing far red light in 32 peripheral artery disease patients.¹¹ The primary endpoints are six-minute walk distance and lower extremity perfusion, with secondary measures including plasma nitrite levels and muscle perfusion on MRI. It's well-designed. It's also still recruiting, with results expected in 2026.

Until the LIGHT PAD results arrive, we have exactly zero completed, blinded, controlled human trials testing whether photobiomodulation can affect atherosclerotic plaque or meaningfully improve outcomes in cardiovascular disease patients.

$545 to $8,395 for a Device Cleared for Wrinkles, Not Arteries

The consumer red light therapy market has exploded. Joovv, the market leader, sells panels ranging from $545 (the handheld Go 2.0) to $8,395 (the full-body Elite system). Other manufacturers like Theralight and dozens of Amazon-listed brands compete at lower price points, typically $200–$1,500.¹²

Here's the regulatory reality: most consumer red light panels are FDA Class II devices, cleared via the 510(k) pathway. This means they've demonstrated "substantial equivalence" to a predicate device — not that they've been proven effective for any specific condition. The clearances are typically limited to claims like "temporary relief of minor pain" or "reduction of wrinkles." No consumer red light device has FDA clearance for atherosclerosis, arterial plaque, or cardiovascular disease of any kind.¹²

A 2024 analysis in Cureus examined how red light therapy is promoted on social media and found that 64.4% of posts were created by non-credentialed authors, compared to just 18.2% by physicians. The study concluded that social media promotion of red light therapy devices has run well ahead of the substantiated evidence base, with cardiovascular claims among the most egregious stretches.¹³

I want to emphasize: the safety concern here isn't the light itself. PBM devices appear genuinely safe for short-term use. The danger is the narrative — telling people that a light panel can replace statins, aspirin, or lifestyle interventions that have robust clinical evidence behind them. That narrative, based on a single unreplicated rabbit study, is irresponsible.

Elegant Science, Exciting Animals, Missing Humans